Patents by Inventor Hugues Chareat

Hugues Chareat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies raised against proteins of Leishmania which are expressed at an increased level in the amastigote form
    Patent number: 5827671
    Abstract: Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falciparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 27, 1998
    Assignee: McGill University
    Inventors: Gregory Matlashewski, Hugues Chareat
  • A2 gene of leishmania which is differentially-expressed in amastigote form
    Patent number: 5733778
    Abstract: Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falciparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: March 31, 1998
    Inventors: Gregory Matlashewski, Hugues Chareat